RAPT Therapeutics, Inc.

NasdaqGM:RAPT 株式レポート

時価総額：US$1.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

RAPT Therapeutics 過去の業績

過去 基準チェック /06

RAPT Therapeuticsの収益は年間平均-16.6%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間33.8% 66.5%割合で 減少しています。

主要情報

-16.57%

収益成長率

5.01%

EPS成長率

Biotechs 業界の成長17.04%
収益成長率-66.47%
株主資本利益率-69.51%
ネット・マージンn/a
前回の決算情報30 Sep 2025

最近の業績更新

Recent updates

Seeking Alpha • Jan 20

RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate

Summary RAPT Therapeutics, Inc. is being acquired by GSK plc, aka GlaxoSmithKline, for $2.2 billion, driven by its promising anti-IgE antibody ozureprubart. Ozureprubart offers a potential best-in-class profile with extended half-life, enabling dosing every 8–12 weeks versus XOLAIR’s 2–4 weeks. The Phase 2b prestIgE trial is underway for IgE-mediated food allergy, leveraging strong proof-of-concept data in chronic spontaneous urticaria. I maintain a Buy rating on RAPT, citing pipeline progress, the acquisition that happened, and the broad applicability of ozureprubart to IgE-mediated disorders. Read the full article on Seeking Alpha
分析記事 • Jul 16

We're Keeping An Eye On RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Mar 28

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Feb 16

Still Cautious Over RAPT Therapeutics' Fresh Start With RPT904

Summary RAPT Therapeutics pivoted from a failed inflammation asset (RPT193) to focus on RPT904 for food allergies. RPT904, an IgE-inhibiting mAb licensed from Jemincare, is in Phase 2 for food allergy, CSU, and asthma. The licensing deal includes a $35 million upfront fee plus milestones and royalties, with rights outside China, Hong Kong, and Macau. This gives RAPT a new “fresh start” with roughly $241.4 million in resources to fund its latest bet on RPT904 targeting FA. However, I’m still neutral on RAPT, as the recently issued shares could be a headwind. Also, the company’s bet on RPT904 remains speculative until Jemincare reports its Phase 2 data. Read the full article on Seeking Alpha
分析記事 • Nov 10

Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 24

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Summary Data from phase 2b study, using zelnecirnon for the treatment of patients with atopic dermatitis, is expected in Q3 of 2024; Potential for FDA clinical hold to be removed. The global atopic dermatitis market is expected to reach a valuation of $19.49 billion by the end of 2034. Preliminary ORR data established shows that tivumecirnon might ultimately be effective in treating CPI-naive NSCLC and CPI-experienced advanced HNSCC patients. The company had $141.6 million in cash as of March 31st of 2024; enough to fund its operations for at least the next 12 months. Read the full article on Seeking Alpha
分析記事 • Jun 13

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • May 20

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

Summary RAPT Therapeutics' lead candidate, zelnecirnon, is in phase 2 for atopic dermatitis and asthma with very promising ph1b results in atopic dermatitis and potential expansion in multiple indications. Liver failure in a single patient with a complex medical history resulted in a clinical hold by the FDA, leaving RAPT no choice but to unblind both ongoing ph2 studies. The probability that zelnecirnon caused the hepatic failure is low considering alternative explanations and no prior preclinical/clinical evidence of liver toxicity. If ph1b results are replicated, I expect the ph2 readout to be positive with available patients, despite premature halting of the trial. Subsequently, I expect the lifting of the FDA clinical hold. Read the full article on Seeking Alpha
分析記事 • Feb 21

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Sep 12

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • May 10

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Feb 07

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Oct 12

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Jan 25

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Oct 15

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Jun 08

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Mar 15

Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

収支内訳

RAPT Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGM:RAPT 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Sep 250-1063083
30 Jun 250-1062984
31 Mar 250-1172894
31 Dec 240-13029107
30 Sep 240-1072788
30 Jun 240-12028101
31 Mar 240-11828100
31 Dec 230-11726101
30 Sep 230-1092594
30 Jun 230-992383
31 Mar 231-932176
31 Dec 222-842067
30 Sep 222-792062
30 Jun 223-761861
31 Mar 223-731760
31 Dec 214-691657
30 Sep 214-641554
30 Jun 215-601451
31 Mar 215-561349
31 Dec 205-531345
30 Sep 204-531245
30 Jun 202-491040
31 Mar 201-471038
31 Dec 190-43935
30 Sep 190-39733
30 Jun 190-40734
31 Mar 190-37632
31 Dec 180-36532

質の高い収益: RAPTは現在利益が出ていません。

利益率の向上: RAPTは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: RAPTは利益が出ておらず、過去 5 年間で損失は年間16.6%の割合で増加しています。

成長の加速: RAPTの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: RAPTは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。

株主資本利益率

高いROE: RAPTは現在利益が出ていないため、自己資本利益率 ( -69.51% ) はマイナスです。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/03/05 08:36
終値2026/03/02 00:00
収益2025/09/30
年間収益2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

RAPT Therapeutics, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7

アナリスト機関
Gao Yi ChenBerenberg
Guyn KimBMO Capital Markets Equity Research
Zegbeh JallahCapital One Securities, Inc.